NICE issued updated guidance that supports payer reimbursement for Genmab’s tisotumab vedotin (Tivdak), an antibody-drug conjugate for recurrent or metastatic cervical cancer. The decision overturns a prior March rejection on cost-effectiveness uncertainties, which the regulator said were mitigated by a confidential discount with NHS England.